Myelofibrosis – Optimising myelofibrosis management with new and emerging therapies
Dr Jean-Jacques Kiladjian (Université Paris Cité, Paris, France), Dr Claire Harrison (Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai (ISMMS), New York, USA) and Prof Adam Mead (University of Oxford, Oxford, UK) discuss optimising myelofibrosis management with current and emerging therapies.
The discussion covers a wide range of topics, including both current and emerging therapies, as well as available data and expert recommendations on risk stratification, molecular features, cytogenetics, and symptom burden. Additionally, the panellists explore suboptimal first-line treatment responses and strategies aimed at reducing transfusion dependence in patients with MF. They highlight the importance of multidisciplinary collaboration and individualised treatment plans to ensure the highest quality of care for MF patients. Patient assessment criteria are also discussed in depth.